Patents by Inventor Hunter Clay Champion

Hunter Clay Champion has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220088065
    Abstract: Disclosed herein are methods for treating acute or chronic heart failure using inorganic nitrite, such as sodium nitrite. The method includes administering to a subject in need of treatment a therapeutically effective amount of inorganic nitrite. The nitrite may be administered by inhalation and may be nebulized. The nitrite may be administered at an emitted dose or in an escalated titrated dose. The nitrite may be a liquid formulation or a dry powder formulation.
    Type: Application
    Filed: December 2, 2021
    Publication date: March 24, 2022
    Inventors: Mark Thomas Gladwin, Edwin Parsley, Hunter Clay Champion
  • Patent number: 11219640
    Abstract: Disclosed herein are methods for treating acute or chronic heart failure using inorganic nitrite, such as sodium nitrite. The method includes administering to a subject in need of treatment a therapeutically effective amount of inorganic nitrite. The nitrite may be administered by inhalation and may be nebulized. The nitrite may be administered at an emitted dose or in an escalated titrated dose. The nitrite may be a liquid formulation or a dry powder formulation.
    Type: Grant
    Filed: April 16, 2018
    Date of Patent: January 11, 2022
    Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education, Aires Pharmaceuticals, Inc.
    Inventors: Mark Thomas Gladwin, Hunter Clay Champion, Edwin Parsley
  • Publication number: 20180360873
    Abstract: Disclosed herein are methods for treating acute or chronic heart failure using inorganic nitrite, such as sodium nitrite. Sodium nitrite is a naturally occurring compound that is commonly used as a preservative in meats. Due to its vasodilative properties and involvement in the nitric oxide pathway, drug development companies and researchers are also investigating sodium nitrite as a therapeutic agent.
    Type: Application
    Filed: April 16, 2018
    Publication date: December 20, 2018
    Inventors: Mark Thomas Gladwin, Hunter Clay Champion, Edwin Parsley
  • Publication number: 20170276688
    Abstract: Hypoxia induced mitogenic factor (HIMF) is a member of the “found in inflammatory zone” (FIZZ)/resistin family of proteins and has potent mitogenic, angiogenic, and vasoconstrictive effects in the lung vasculature. The receptor/binding partners for this family of proteins have been largely unknown. We identified Bruton's tyrosine kinase (BTK) as a functional HIMF binding partner through GST-HIMF pull-downs and mass spectrometry. Using primary cultured HIMF-stimulated murine bone marrow cells, we demonstrated that BTK was recruited to the leading edge of the cells. We also demonstrated that BTK and the closely related tyrosine kinase Fyn, colocalized at the growth cone process in these cells. HIMF stimulation induced BTK autophosphorylation, which peaked at 2.5 minutes. A transwell migration assay showed that treatment with recombinant murine HIMF induced migration of primary cultured bone marrow cells, which was completely blocked by the BTK inhibitor, LFM-A13.
    Type: Application
    Filed: December 8, 2016
    Publication date: September 28, 2017
    Inventors: Roger A. Johns, Qingning Su, Hunter Clay Champion
  • Publication number: 20160008394
    Abstract: Disclosed herein are methods for treating acute or chronic heart failure using inorganic nitrite, such as sodium nitrite. Sodium nitrite is a naturally occurring compound that is commonly used as a preservative in meats. Due to its vasodilative properties and involvement in the nitric oxide pathway, drug development companies and researchers are also investigating sodium nitrite as a therapeutic agent.
    Type: Application
    Filed: February 28, 2014
    Publication date: January 14, 2016
    Inventors: Mark Thomas Gladwin, Hunter Clay Champion, Edwin Parsley
  • Publication number: 20150276761
    Abstract: Hypoxia induced mitogenic factor (HIMF) is a member of the “found in inflammatory zone” (FIZZ)/resistin family of proteins and has potent mitogenic, angiogenic, and vasoconstrictive effects in the lung vasculature. The receptor/binding partners for this family of proteins have been largely unknown. We identified Bruton's tyrosine kinase (BTK) as a functional HIMF binding partner through GST-HIMF pull-downs and mass spectrometry. Using primary cultured HIMF-stimulated murine bone marrow cells, we demonstrated that BTK was recruited to the leading edge of the cells. We also demonstrated that BTK and the closely related tyrosine kinase Fyn, colocalized at the growth cone process in these cells. HIMF stimulation induced BTK autophosphorylation, which peaked at 2.5 minutes. A transwell migration assay showed that treatment with recombinant murine HIMF induced migration of primary cultured bone marrow cells, which was completely blocked by the BTK inhibitor, LFM-A13.
    Type: Application
    Filed: April 3, 2015
    Publication date: October 1, 2015
    Inventors: Roger A. Johns, Qingning Su, Hunter Clay Champion
  • Publication number: 20140080151
    Abstract: Hypoxia induced mitogenic factor (HIMF) is a member of the “found in inflammatory zone” (FIZZ)/resistin family of proteins and has potent mitogenic, angiogenic, and vasoconstrictive effects in the lung vasculature. The receptor/binding partners for this family of proteins have been largely unknown. We identified Bruton's tyrosine kinase (BTK) as a functional HIMF binding partner through GST-HIMF pull-downs and mass spectrometry. Using primary cultured HIMF-stimulated murine bone marrow cells, we demonstrated that BTK was recruited to the leading edge of the cells. A transwell migration assay showed that treatment with recombinant murine HIMF induced migration of primary cultured bone marrow cells, which was completely blocked by a BTK inhibitor. In vivo studies revealed that HIMF can stimulate angiogenesis in the hypoxic tissue.
    Type: Application
    Filed: November 29, 2012
    Publication date: March 20, 2014
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Roger A. Johns, Qingning Su, Hunter Clay Champion
  • Patent number: 8343491
    Abstract: Hypoxia induced mitogenic factor (HIMF) is a member of the “found in inflammatory zone” (FIZZ)/resistin family of proteins and has potent mitogenic, angiogenic, and vasoconstrictive effects in the lung vasculature. We use antibodies to HIMF to treat certain diseases including adult respiratory distress syndrome, radiation-induced pulmonary fibrosis, idiopathic pulmonary fibrosis, and emphysema.
    Type: Grant
    Filed: December 18, 2007
    Date of Patent: January 1, 2013
    Assignee: The Johns Hopkins University
    Inventors: Roger A. Johns, Qingning Su, Hunter Clay Champion
  • Publication number: 20100028355
    Abstract: Hypoxia induced mitogenic factor (HIMF) is a member of the “found in inflammatory zone” (FIZZ)/resistin family of proteins and has potent mitogenic, angiogenic, and vasoconstrictive effects in the lung vasculature. The receptor/binding partners for this family of proteins have been largely unknown. We identified Bruton's tyrosine kinase (BTK) as a functional HIMF binding partner through GST-HIMF pull-downs and mass spectrometry. Using primary cultured HIMF-stimulated murine bone marrow cells, we demonstrated that BTK was recruited to the leading edge of the cells. We also demonstrated that BTK and the closely related tyrosine kinase Fyn, colocalized at the growth cone process in these cells. HIMF stimulation induced BTK autophosphorylation, which peaked at 2.5 minutes. A transwell migration assay showed that treatment with recombinant murine HIMF induced migration of primary cultured bone marrow cells, which was completely blocked by the BTK inhibitor, LFM-A13.
    Type: Application
    Filed: December 18, 2007
    Publication date: February 4, 2010
    Applicant: The Johns Hopkins University
    Inventors: Roger A. Johns, Qingning Su, Hunter Clay Champion